| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | 10%+ Owner | $4.93M | Oct 12, 2021 | ||
| Foresite Capital Management V, LLC | 10%+ Owner | $4.23M | Jul 17, 2023 | ||
| Omega Fund VI, L.P. | Former 10% owner | $2.17M | Oct 12, 2021 | ||
| William Shakespeare | President of Research and Development | $2.02M | Nov 6, 2023 | ||
| Rock Springs Capital Management LP | 10%+ Owner | $1.83M | Oct 12, 2021 | ||
| Timothy P. Clackson | President and CEO, Director | $1.21M | Mar 1, 2023 | ||
| David Dalgarno | Chief Technical Officer | $1.18M | Feb 18, 2022 | ||
| David Kerstein | Chief Medical Officer | $53.4K | Mar 1, 2023 | ||
| Victor Rivera | Chief Scientific Officer | $49.6K | Mar 1, 2023 | ||
| Iain Dukes | Director | $0 | Feb 14, 2024 | ||
| Kathy Yi | Director | $0 | Feb 14, 2024 | ||
| Orbimed Advisors Llc | Director, 10%+ Owner | $0 | Feb 14, 2024 | ||
| Donald J. Hayden Jr | Director | $0 | Feb 14, 2024 | ||
| Steven H. Stein | Director | $0 | Feb 14, 2024 | ||
| D. Dahms | President and CFO | $0 | Feb 14, 2024 | ||
| Carl L. Gordon | Director, 10%+ Owner | $0 | Feb 14, 2024 | ||
| Michael E. Rome | Director | Oct 6, 2021 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|